Today’s Stock On Watch: Is Aptose Biosciences Incorporated (NASDAQ:APTO)’s Fuel Running Low? Reports Show More Sellers

November 24, 2016 - By Dolores Ford   ·   0 Comments

Today's Stock On Watch: Is Aptose Biosciences Incorporated (NASDAQ:APTO)’s Fuel Running Low? Reports Show More Sellers

The stock of Aptose Biosciences Incorporated (NASDAQ:APTO) registered an increase of 34.96% in short interest. APTO’s total short interest was 160,600 shares in November as published by FINRA. Its up 34.96% from 119,000 shares, reported previously. With 197,000 shares average volume, it will take short sellers 1 days to cover their APTO’s short positions. The short interest to Aptose Biosciences Incorporated’s float is 1.68%. The stock decreased 2.14% or $0.021 on November 23, hitting $0.959. About 75,066 shares traded hands. Aptose Biosciences Inc (NASDAQ:APTO) has declined 62.06% since April 22, 2016 and is downtrending. It has underperformed by 67.46% the S&P500.

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company has a market cap of $12.51 million. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. It currently has negative earnings. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Aptose Biosciences Inc (NASDAQ:APTO) Ratings Coverage

Out of 3 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Aptose Biosciences has been the topic of 6 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Zacks upgraded the shares of APTO in a report on Friday, August 7 to “Hold” rating. As per Wednesday, November 16, the company rating was maintained by RBC Capital Markets. The stock of Aptose Biosciences Inc (NASDAQ:APTO) has “Neutral” rating given on Friday, November 20 by Roth Capital. TH Capital downgraded the stock to “Neutral” rating in Friday, November 20 report. RBC Capital Markets maintained the shares of APTO in a report on Wednesday, November 11 with “Outperform” rating. Roth Capital upgraded the shares of APTO in a report on Monday, June 13 to “Buy” rating.

APTO Company Profile

Aptose Biosciences Inc. (Aptose), incorporated on November 1, 2006, is a clinical-stage biotechnology company. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Firm develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products.

More recent Aptose Biosciences Inc (NASDAQ:APTO) news were published by: Globenewswire.com which released: “Aptose Biosciences Reports Financial Results for the Third Quarter Ended …” on November 15, 2016. Also Quotes.Wsj.com published the news titled: “News Aptose Biosciences Inc.APTO” on October 24, 2014. Streetinsider.com‘s news article titled: “Aptose Biosciences (APTO) Updates on APTO-253 FDA Clinical Hold; Says …” with publication date: October 13, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>